Fleecing The Public

Fleecing The Public Your account of Sen. William Proxmire’s “Golden Fleece” awards (The Scientist, December 12, 1988, page 17) may be supplemented with the history of his success in obstructing regulation of vitamin products in 1974. The Food and Drug Administration proposed to set an upper limit of 150% of Recommended Daily Allowances (RDAs) per tablet for the over-the-counter vitamin products. There was no restriction on taking several tablets per day, which actu ally is a

Written byThomas Jukes
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Your account of Sen. William Proxmire’s “Golden Fleece” awards (The Scientist, December 12, 1988, page 17) may be supplemented with the history of his success in obstructing regulation of vitamin products in 1974. The Food and Drug Administration proposed to set an upper limit of 150% of Recommended Daily Allowances (RDAs) per tablet for the over-the-counter vitamin products. There was no restriction on taking several tablets per day, which actu ally is a more efficient way of assimilating vitamins than is a single dose. The best way to inhibit interference by the executive branch is in the halls of Congress, where many health-minded statesmen were deeply impressed by the volume of pro-vitamin mail from their voting constituents. The leader of megavitamin therapy in the upper house was Proxmire, who wrote to me on November 18, 1974: “Let’s face it. The orthodox nutritional community is off base in supporting the FDA’s ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies